Dogwood Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Dogwood Therapeutics, Inc. (DWTX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $543.20 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-14
- Dogwood Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $543.20K, a 735.35% increase year-over-year.
- Dogwood Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $449.42K, a 432.02% increase year-over-year.
- Dogwood Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $48.28K, a 48.80% decline year-over-year.
- Dogwood Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $65.03K, a 56.34% decline year-over-year.
- Dogwood Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $355.64K, a 25.29% decline from fiscal 2024.
- Dogwood Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $476.02K, a 23.22% decline from fiscal 2023.
- Dogwood Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $619.97K, a 6.40% increase from fiscal 2022.
- Dogwood Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $582.66K, a 80.46% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $543.20K 10-Q · filed 2026-08-14 | $992.62K derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $449.42K 10-Q · filed 2026-08-14 | |||
| 2025-12-31 | $355.64K 10-K · filed 2026-03-18 | |||
| 2025-09-30 | $48.28K 10-Q · filed 2025-11-07 | $113.31K derived: sum of 2 quarters · filed 2026-08-14 | $197.78K derived: sum of 3 quarters · filed 2026-08-14 | |
| 2025-06-30 | $65.03K 10-Q · filed 2026-08-14 | $149.50K derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $84.47K 10-Q · filed 2026-08-14 | |||
| 2024-12-31 | $476.02K 10-K · filed 2026-03-18 | |||
| 2024-09-30 | $94.30K 10-Q · filed 2025-11-07 | $243.25K derived: sum of 2 quarters · filed 2025-11-07 | $382.22K derived: sum of 3 quarters · filed 2025-11-07 | |
| 2024-06-30 | $148.95K 10-Q · filed 2025-11-07 | $287.92K derived: sum of 2 quarters · filed 2025-11-07 | ||
| 2024-03-31 | $138.97K 10-Q · filed 2025-11-07 | |||
| 2023-12-31 | $619.97K 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $148.31K 10-Q · filed 2024-11-08 | $309.97K derived: sum of 2 quarters · filed 2024-11-08 | $471.67K derived: sum of 3 quarters · filed 2024-11-08 | |
| 2023-06-30 | $161.66K 10-Q · filed 2024-11-08 | $323.36K derived: sum of 2 quarters · filed 2024-11-08 | ||
| 2023-03-31 | $161.70K 10-Q · filed 2024-11-08 | |||
| 2022-12-31 | $582.66K 10-K/A · filed 2024-03-08 | |||
| 2022-09-30 | $164.27K 10-Q · filed 2023-11-13 | $301.22K derived: sum of 2 quarters · filed 2023-11-13 | $433.13K derived: sum of 3 quarters · filed 2023-11-13 | |
| 2022-06-30 | $136.96K 10-Q · filed 2023-11-13 | $268.86K derived: sum of 2 quarters · filed 2023-11-13 | ||
| 2022-03-31 | $131.91K 10-Q · filed 2023-11-13 | |||
| 2021-12-31 | $322.88K 10-K · filed 2023-03-14 | |||
| 2021-09-30 | $131.91K 10-Q · filed 2022-11-14 | $166.15K derived: sum of 2 quarters · filed 2022-11-14 | $190.97K derived: sum of 3 quarters · filed 2022-11-14 | |
| 2021-06-30 | $34.24K 10-Q · filed 2022-11-14 | $59.07K derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2021-03-31 | $24.82K 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $5.43M 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |